Sugi Predict

Sugi Predict / Compounds / SCHEMBL10175331

SCHEMBL10175331

SCHEMBL10175331

O=[N+]([O-])c1ccc(F)cc1NC1CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.60
▸ GAA P10253 3/20 0.60
▸ GLA P06280 1/20 0.60
▸ MAPK1 P28482 3/20 0.59
▸ CYP1A2 P05177 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ CYP2C19 P33261 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ HCAR3 P49019 3/20 0.52
▸ ATM Q13315 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ ALDH1A1 P00352 3/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ DCTPP1 Q9H773 1/20 0.45
▸ POLB P06746 2/20 0.43
▸ LMNA P02545 3/20 0.42
▸ CRHBP P24387 1/20 0.42
▸ CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11900769 0.94 MAPT (0.57) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL11901731 0.92 MAPT (0.56) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL30936578 0.92 MAPT (0.56) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL11901788 0.89 MAPT (0.51) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL11901791 0.89 MAPT (0.51) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL931990 0.87 HCAR3 (0.64) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL28505132 0.86 MAPT (0.48) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL28505134 0.86 MAPT (0.48) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL550288 0.83 MAPT (0.53) MAPTGAAGLAMAPK1CYP1A2
SCHEMBL572285 0.83 MAPT (0.47) MAPTGAAGLAMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2026-04-09 — — US disclosed
US-12458642-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-11-04 — — US disclosed
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KHORA SPV 1 LLC (US) 2025-10-30 — — US disclosed
US-20250296925-A1 METALLOENZYME INHIBITOR COMPOUNDS CORXEL PHARMACEUTICALS HONG KONG LTD (HK) 2025-09-25 — — US disclosed
US-12358893-B2 Metalloenzyme inhibitor compounds CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) 2025-07-15 — — US disclosed
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases KHORA SPV 1, LLC (US) 2025-06-17 — — US disclosed
EP-3562306-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2025-02-26 — — EP disclosed
US-11919883-B2 Metalloenzyme inhibitor compounds JI XING PHARMACEUTICALS HONG KONG LIMITED (HK) 2024-03-05 — — US disclosed
EP-4311577-A2 METALLOENZYME INHIBITOR COMPOUNDS Ji Xing Pharmaceuticals Hong Kong Limited (HK) 2024-01-31 — — EP disclosed
EP-3562487-B1 METALLOENZYME INHIBITOR COMPOUNDS JI XING PHARMACEUTICALS HONG KONG LTD (HK) 2023-11-29 — — EP disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 — — US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 — — EP disclosed
US-20130317057-A1 ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC 2013-11-28 — — US disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — WO disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 — — WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 — — US disclosed
WO-2012012478-A1 ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358893-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 MAPT 1752/4885GAA 1526/4885GLA 1554/4885
US-12458642-B2 Metalloenzyme inhibitor compounds CYP11B2, CYP11B1, HSD11B2 MAPT 2593/4885GAA 139/4885GLA 1014/4885
US-12331039-B2 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 MAPT 3513/4885GAA 427/4885GLA 1325/4885
US-20250296925-A1 METALLOENZYME INHIBITOR COMPOUNDS SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885
US-20250333399-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 MAPT 3513/4885GAA 427/4885GLA 1325/4885
US-20260097034-A1 METALLOENZYME INHIBITOR COMPOUNDS CPN1, TPP1, DPP4 MAPT 2173/4885GAA 5/4885GLA 581/4885
US-20130317057-A1 ALDOSTERONE SYNTHASE INHIBITORS HSD11B1, CYP11B2, HSD11B2 MAPT 2917/4885GAA 2500/4885GLA 2321/4885
US-11919883-B2 Metalloenzyme inhibitor compounds SOD1, RNASE1, FECH MAPT 2388/4885GAA 4/4885GLA 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.